642
Views
0
CrossRef citations to date
0
Altmetric
General Content - Editorial

How Close are We to Individual Analgesic Adjustment According to a Patient‘s Genotype?

, &
Pages 289-292 | Published online: 31 May 2011

Bibliography

  • Rollason V , SamerC, PiguetV, DayerP, DesmeulesJ: Pharmacogenetics of analgesics: toward the individualization of prescription.Pharmacogenomics9(7) , 905–933 (2008).
  • Freedman AN , SansburyLB, FiggWD et al.: Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.J. Natl Cancer Inst.102(22) , 1698–1705 (2010).
  • Argoff CE : Clinical implications of opioid pharmacogenetics.Clin. J. Pain26(Suppl. 10) , S16–S20 (2010).
  • Samer CF , DesmeulesJA, DayerP: Individualizing analgesic prescription. Part I: pharmacogenetics of opioid analgesics.Pers. Med.3(3) , 239–269 (2006).
  • Samer CF , DesmeulesJA, DayerP: Individualizing analgesic prescription. Part II: pharmacogenetics of anti-inflammatory analgesics and co-analgesics.Pers. Med.3(3) , 271–297 (2006).
  • Stamer UM , ZhangL, StuberF: Personalized therapy in pain management: where do we stand?Pharmacogenomics11(6) , 843–864 (2010).
  • Desmeules J , GasconMP, DayerP, MagistrisM: Impact of environmental and genetic factors on codeine analgesia.Eur. J. Clin. Pharmacol.41(1) , 23–26 (1991).
  • Caraco Y , ShellerJ, WoodAJ: Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.J. Pharmacol. Exp. Ther.278(3) , 1165–1174 (1996).
  • Poulsen L , Arendt-NielsenL, BrosenK, SindrupSH: The hypoalgesic effect of tramadol in relation to CYP2D6.Clin. Pharmacol. Ther.60(6) , 636–644 (1996).
  • Stamer UM , LehnenK, HothkerF et al.: Impact of CYP2D6 genotype on postoperative tramadol analgesia.Pain105(1–2) , 231–238 (2003).
  • Samer CF , DaaliY, WagnerM et al.: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Br. J. Pharmacol.160(4) , 907–918 (2010).
  • Samer CF , DaaliY, WagnerM et al.: Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.Br. J. Pharmacol.160(4) , 919–930 (2010).
  • Brousseau DC , McCarverDG, DrendelAL, DivakaranK, PanepintoJA: The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.J. Pediatr.150(6) , 623–626 (2007).
  • Kirchheiner J , KeulenJT, BauerS, RootsI, BrockmollerJ: Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.J. Clin. Psychopharmacol.28(1) , 78–83 (2008).
  • Koren G , CairnsJ, ChitayatD, GaedigkA, LeederSJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.Lancet368(9536) , 704 (2006).
  • Steimer W , ZopfK, von Amelunxen S et al.: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem.51(2) , 376–385 (2005).
  • Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry9(5) , 442–473 (2004).
  • Kirchheiner J , BrosenK, DahlML et al.: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Acta Psychiatr. Scand.104(3) , 173–192 (2001).
  • Gasche Y , DaaliY, FathiM et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism.N. Engl. J. Med.351(27) , 2827–2831 (2004).
  • Niemi M , BackmanJT, FrommMF, NeuvonenPJ, KivistoKT: Pharmacokinetic interactions with rifampicin: clinical relevance.Clin. Pharmacokinet.42(9) , 819–850 (2003).
  • Herrlin K , SegerdahlM, GustafssonLL, KalsoE: Methadone, ciprofloxacin, and adverse drug reactions.Lancet356(9247) , 2069–2070 (2000).
  • Collart L , LuthyC, Favario-ConstantinC, DayerP: [Duality of the analgesic effect of tramadol in humans].Schweiz Med. Wochenschr.123(47) , 2241–2243 (1993).
  • Desmeules JA , OestreicherMK, PiguetV, AllazAF, DayerP: Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.J. Pharmacol. Exp. Ther.288(2) , 607–612 (1999).
  • Thisted RA , KlaffL, SchwartzSL et al.: Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.Clin. Ther.28(10) , 1607–1618 (2006).
  • Panitch HS , ThistedRA, SmithRA et al.: Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.Ann. Neurol.59(5) , 780–787 (2006).
  • Allegri M , De Gregori M, Niebel T et al.: Pharmacogenetics and postoperative pain: a new approach to improve acute pain management. Minerva Anestesiol.76(11) , 937–944 (2010).
  • Kosarac B , FoxAA, CollardCD: Effect of genetic factors on opioid action.Curr. Opin. Anaesthesiol.22(4) , 476–482 (2009).
  • Lee YS , KimH, WuTX, WangXM, DionneRA: Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs.Clin. Pharmacol. Ther.79(5) , 407–418 (2006).
  • Zubieta JK , HeitzegMM, SmithYR et al.: COMT val158met genotype affects µ-opioid neurotransmitter responses to a pain stressor.Science299(5610) , 1240–1243 (2003).
  • Mogil JS , RitchieJ, SmithSB et al.: Melanocortin-1 receptor gene variants affect pain and µ-opioid analgesia in mice and humans.J. Med. Genet.42(7) , 583–587 (2005).
  • Rakvag TT , KlepstadP, BaarC et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.Pain116(1–2) , 73–78 (2005).
  • Shah RR : Pharmacogenetics in drug regulation: promise, potential and pitfalls.Philos. Trans. R. Soc. Lond. B Biol. Sci.360(1460) , 1617–1638 (2005).
  • Lotsch J , FluhrK, NeddermayerT, DoehringA, GeisslingerG: The consequence of concomitantly present functional genetic variants for the identification of functional genotype–phenotype associations in pain.Clin. Pharmacol. Ther.85(1) , 25–30 (2009).
  • Campa D , GioiaA, TomeiA, PoliP, BaraleR: Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.Clin. Pharmacol. Ther.83(4) , 559–566 (2008).
  • Reyes-Gibby CC , SheteS, RakvågT et al.: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.Pain130(1–2) , 25–30 (2007).
  • Lotsch J , GeisslingerG: Current evidence for a genetic modulation of the response to analgesics.Pain121(1–2) , 1–5 (2006).
  • Kim H , ClarkD, DionneRA: Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research.J. Pain10(7) , 663–693 (2009).
  • Lotsch J , GeisslingerG, TegederI: Genetic modulation of the pharmacological treatment of pain.Pharmacol. Ther.124(2) , 168–184 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.